Dosing & Uses
Dosage Forms & Strengths
cream
- 0.05%
ointment
- 0.05%
Inflammatory & Pruritic Skin Disorders
Apply thin film to affected area q8-12hr; discontinue treatment when control achieved
Reassess diagnosis if no improvement within 2 weeks
Dosage Forms & Strengths
cream
- 0.05%
ointment
- 0.05%
Inflammatory & Pruritic Skin Disorders
Apply thin film to affected area q8-12hr; discontinue treatment when control achieved
Reassess diagnosis if no improvement within 2 weeks
Adverse Effects
Frequency Not Defined
Skin atrophy
Hypopigmentation
Miliaria
Cushing's syndrome
Dryness
Striae
Acneform lesions
Secondary infection
Irritation
HPA suppression (with higher potency used >2 wk)
Warnings
Contraindications
Hypersensitivity
Underlying infection
Herpes simplex, varicella, vaccinia
Acne, rosacea, perioral dermatitis
Ophthalmic use
Cautions
Chronic topical corticosteroid therapy may interfere with growth and development in children
Pregnancy
Breastfeeding
Development of Kaposi's sarcoma with prolonged use reported (discontinue therapy if it occurs)
Use medium to very high potency for <2 wk to reduce local and systemic side effects
Use low potency for chronic therapy
Adrenal suppression may occur in younger patients or patients receiving high doses for prolonged periods
Avoid medium to very high potency on face, folds, groin because can increase steroid absorption
Use lower potency for peds (ie, increase BSA/kg, therefore increase systemic absorption)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Use with caution.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation
Pharmacokinetics
Absorption: 3% absorbed systemically after 8 hr following skin application
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.